Westpac Banking Corp Acquires 2,716 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Westpac Banking Corp raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 39.4% during the 1st quarter, HoldingsChannel reports. The fund owned 9,604 shares of the biopharmaceutical company’s stock after acquiring an additional 2,716 shares during the quarter. Westpac Banking Corp’s holdings in Regeneron Pharmaceuticals were worth $7,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Kemnay Advisory Services Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. Finally, Entrust Financial LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $32,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.5%

NASDAQ REGN opened at $675.19 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market cap of $71.38 billion, a PE ratio of 16.45, a P/E/G ratio of 1.49 and a beta of 0.24. The stock’s 50 day moving average is $639.22 and its 200 day moving average is $716.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% on a year-over-year basis. During the same period last year, the firm posted $8.22 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on REGN shares. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 8th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $787.88.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued analyst confidence in the company’s longer-term outlook.
• Neutral Sentiment: Regeneron said it completed a mid-stage study for REGN7544 in POTS, which could be relevant for its pipeline, but the market impact is unclear from the update alone.
• Negative Sentiment: Multiple law firms announced or reminded investors about a pending class action lawsuit against Regeneron related to disclosures around a Phase 3 melanoma study failure, reinforcing legal and reputational risk for the stock.
• Negative Sentiment: The lawsuit filings and deadline reminders suggest the company faces ongoing litigation risk and potential distraction as investors focus on trial disclosure concerns rather than near-term fundamentals.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.